Jennifer Bacik

9.9k total citations · 4 hit papers
43 papers, 7.4k citations indexed

About

Jennifer Bacik is a scholar working on Pulmonary and Respiratory Medicine, Surgery and Molecular Biology. According to data from OpenAlex, Jennifer Bacik has authored 43 papers receiving a total of 7.4k indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Pulmonary and Respiratory Medicine, 23 papers in Surgery and 12 papers in Molecular Biology. Recurrent topics in Jennifer Bacik's work include Testicular diseases and treatments (19 papers), Renal cell carcinoma treatment (18 papers) and Ovarian cancer diagnosis and treatment (9 papers). Jennifer Bacik is often cited by papers focused on Testicular diseases and treatments (19 papers), Renal cell carcinoma treatment (18 papers) and Ovarian cancer diagnosis and treatment (9 papers). Jennifer Bacik collaborates with scholars based in United States, Germany and United Kingdom. Jennifer Bacik's co-authors include Robert J. Motzer, Madhu Mazumdar, Paul Russo, William J. Berg, Barbara A. Murphy, Alison Amsterdam, Joseph M. Ferrara, Victor E. Reuter, Dean F. Bajorin and George J. Bosl and has published in prestigious journals such as JAMA, Journal of Clinical Oncology and Cancer.

In The Last Decade

Jennifer Bacik

43 papers receiving 7.2k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Survival and Prognostic Stratification of 670 Patients With Advanced Renal Cell Carcinoma

1999 1.4k citations Robert J. Motzer, Madhu Mazumdar et al. Journal of Clinical Oncology profile →
Interferon-Alfa as a Comparative Treatment for Clinical Trials of New Therapies Against Advanced Renal Cell Carcinoma

2002 1.2k citations Robert J. Motzer, Jennifer Bacik et al. Journal of Clinical Oncology profile →
Sunitinib in Patients With Metastatic Renal Cell Carcinoma

2006 969 citations Robert J. Motzer, Brian I. Rini et al. JAMA profile →
Prognostic Factors for Survival in Previously Treated Patients With Metastatic Renal Cell Carcinoma

2004 609 citations Robert J. Motzer, Jennifer Bacik et al. Journal of Clinical Oncology profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Jennifer Bacik	5.0k	3.8k	2.3k	2.2k	2.1k	43	7.4k
Christine Théodore	6.0k 1.2×	2.1k 0.5×	1.7k 0.8×	3.9k 1.8×	3.5k 1.6×	164	10.5k
Aude Fléchon	4.9k 1.0×	1.8k 0.5×	1.5k 0.7×	2.0k 0.9×	2.6k 1.2×	273	7.7k
I. Bodrogi	6.4k 1.3×	4.3k 1.1×	2.9k 1.3×	2.4k 1.1×	3.6k 1.7×	78	10.3k
Federica Perrone	2.7k 0.6×	2.1k 0.6×	1.3k 0.6×	2.0k 0.9×	3.6k 1.7×	235	7.9k
Xavier García del Muro	3.2k 0.6×	1.9k 0.5×	974 0.4×	1.9k 0.9×	1.7k 0.8×	186	5.3k
Gwénaëlle Gravis	6.3k 1.3×	2.2k 0.6×	2.1k 1.0×	1.4k 0.6×	3.4k 1.6×	368	9.2k
Frédéric Rolland	6.7k 1.4×	4.8k 1.2×	3.0k 1.3×	2.7k 1.2×	4.3k 2.0×	142	11.6k
Tarek Sahmoud	4.9k 1.0×	2.1k 0.5×	1.8k 0.8×	3.1k 1.4×	5.1k 2.4×	130	11.3k
Joan Carles	3.1k 0.6×	1.2k 0.3×	1.0k 0.4×	2.5k 1.2×	2.4k 1.1×	327	6.2k
Philippe Beuzeboc	3.2k 0.7×	1.2k 0.3×	2.4k 1.1×	1.6k 0.7×	3.9k 1.8×	243	7.6k

Countries citing papers authored by Jennifer Bacik

Since Specialization

Citations

This map shows the geographic impact of Jennifer Bacik's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jennifer Bacik with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jennifer Bacik more than expected).

Fields of papers citing papers by Jennifer Bacik

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jennifer Bacik. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jennifer Bacik. The network helps show where Jennifer Bacik may publish in the future.

Co-authorship network of co-authors of Jennifer Bacik

This figure shows the co-authorship network connecting the top 25 collaborators of Jennifer Bacik. A scholar is included among the top collaborators of Jennifer Bacik based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jennifer Bacik. Jennifer Bacik is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Patel, Premal H., G. Varuni Kondagunta, Lawrence H. Schwartz, et al.. (2007). Phase II trial of lenalidomide in patients with metastatic renal cell carcinoma. Investigational New Drugs. 26(3). 273–276. 16 indexed citations

Royston, Patrick, Jennifer Bacik, Paul Elson, Judith Manola, & Madhu Mazumdar. (2007). A consensus prognostic factor model for survival in patients with metastatic renal cell carcinoma: A Kidney Cancer Association’s International Kidney Cancer Working Group (IKCWG) study. Journal of Clinical Oncology. 25(18_suppl). 5109–5109. 1 indexed citations

Motzer, Robert J., Brian I. Rini, Ronald M. Bukowski, et al.. (2006). Sunitinib in Patients With Metastatic Renal Cell Carcinoma. JAMA. 295(21). 2516–2516. 969 indexed citations breakdown →

Ronnen, Ellen A., G. Varuni Kondagunta, Nicole Ishill, et al.. (2006). A phase II trial of 17-(Allylamino)-17-demethoxygeldanamycin in patients with papillary and clear cell renal cell carcinoma. Investigational New Drugs. 24(6). 543–546. 125 indexed citations

Ronnen, Ellen A., G. Varuni Kondagunta, Nicole Ishill, et al.. (2006). Treatment outcome for metastatic papillary renal cell carcinoma patients. Cancer. 107(11). 2617–2621. 68 indexed citations

Eton, David T., David Cella, Jennifer Bacik, & Robert J. Motzer. (2006). A brief symptom index for advanced renal cell carcinoma. Health and Quality of Life Outcomes. 4(1). 68–68. 10 indexed citations

Bajorin, Dean F., Chelsea Nichols, Kim Margolin, et al.. (2006). Phase III trial of conventional-dose chemotherapy alone or with high-dose chemotherapy for metastatic germ cell tumors (GCT) patients (PTS): A cooperative group trial by Memorial Sloan-Kettering Cancer Center, ECOG, SWOG, and CALGB. Journal of Clinical Oncology. 24(18_suppl). 4510–4510. 11 indexed citations

Camacho, Luis H., Jennifer Bacik, Alexander Cheung, & David R. Spriggs. (2005). Presentation and subsequent publication rates of phase I oncology clinical trials. Cancer. 104(7). 1497–1504. 42 indexed citations

Temple, Larissa K., Jennifer Bacik, Lester Gottesman, et al.. (2005). The Development of a Validated Instrument to Evaluate Bowel Function After Sphincter-Preserving Surgery for Rectal Cancer. Diseases of the Colon & Rectum. 48(7). 1353–1365. 224 indexed citations

10.

Ronnen, Ellen A., G. Varuni Kondagunta, Jennifer Bacik, et al.. (2005). Incidence of Late-Relapse Germ Cell Tumor and Outcome to Salvage Chemotherapy. Journal of Clinical Oncology. 23(28). 6999–7004. 49 indexed citations

11.

Kondagunta, G. Varuni, Jennifer Bacik, Dean F. Bajorin, et al.. (2005). Sequential dose-intensive paclitaxel plus ifosfamide and carboplatin plus etoposide with autologous stem cell transplantation for germ cell tumor (GCT) patients (pts). Journal of Clinical Oncology. 23(16_suppl). 4503–4503. 5 indexed citations

12.

Kondagunta, G. Varuni, Jennifer Bacik, Lawrence Schwartz, et al.. (2004). Phase II Trial of Temozolomide in Patients with Cisplatin-Refractory Germ Cell Tumors. Investigational New Drugs. 22(2). 177–179. 9 indexed citations

13.

Koul, Sanjay, James M. McKiernan, Gopeshwar Narayan, et al.. (2004). Role of promoter hypermethylation in Cisplatin treatment response of male germ cell tumors.. Molecular Cancer. 3(1). 16–16. 116 indexed citations

14.

Bacik, Jennifer, Madhu Mazumdar, Barbara A. Murphy, et al.. (2004). The functional assessment of cancer therapy–BRM (FACT–BRM): A new tool for the assessment of quality of life in patients treated with biologic response modifiers. Quality of Life Research. 13(1). 137–154. 33 indexed citations

15.

Bacik, Jennifer, Michelle S. Ginsberg, Stéphanie Marion, et al.. (2003). Phase II trial of ZD1839 (IRESSA™) in patients with advanced renal cell carcinoma. Investigational New Drugs. 21(3). 341–345. 71 indexed citations

16.

Mazumdar, Madhu, Alex Smith, & Jennifer Bacik. (2003). Methods for categorizing a prognostic variable in a multivariable setting. Statistics in Medicine. 22(4). 559–571. 94 indexed citations

17.

McKiernan, James M., Robert J. Motzer, Dean F. Bajorin, et al.. (2003). Reoperative retroperitoneal surgery for nonseminomatous germ cell tumor: clinical presentation, patterns of recurrence, and outcome. Urology. 62(4). 732–736. 66 indexed citations

18.

Motzer, Robert J., Jennifer Bacik, Barbara A. Murphy, Paul Russo, & Madhu Mazumdar. (2002). Interferon-Alfa as a Comparative Treatment for Clinical Trials of New Therapies Against Advanced Renal Cell Carcinoma. Journal of Clinical Oncology. 20(1). 289–296. 1184 indexed citations breakdown →

19.

Tickoo, Satish K., Brian Hutchinson, Jennifer Bacik, et al.. (2002). Testicular Seminoma: A Clinicopathologic and Immunohistochemical Study of 105 Cases with Special Reference to Seminomas with Atypical Features. International Journal of Surgical Pathology. 10(1). 23–32. 57 indexed citations

20.

Vuky, Jacqueline, Manjit S. Bains, Jennifer Bacik, et al.. (2001). Role of Postchemotherapy Adjunctive Surgery in the Management of Patients With Nonseminoma Arising From the Mediastinum. Journal of Clinical Oncology. 19(3). 682–688. 63 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact